imgatuzumab
mAbexperimental
Imgatuzumab (INN) is a humanized monoclonal antibody designed for the treatment of cancer. It is an anti-EGFR antibody that acts as an immunomodulator. — Wikipedia
Clinical trial activity
6 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2008 (NCT00721266)
Timeline
Indications
Mechanism of action
- Epidermal growth factor receptor erbB1ANTAGONIST
EGFR antagonist
Induces antibody-dependent cell-mediated cytotoxicity (ADCC).
- Low affinity immunoglobulin gamma Fc region receptor III-ACROSS-LINKING AGENT
FCGR3A cross-linking agent
EGFR inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaImgatuzumab ↗
- ChEMBLCHEMBL2109394 ↗
- ChEMBLCHEMBL2109393 ↗
- ChEMBLCHEMBL2109389 ↗
Also known as
- ga201
- ga 201
- ga-201
- ga201 mab
- humab<egfr>
- imgatuzumab
- rg7160
- rg 7160
- rg-7160
- rg-7160
- ro5083945
- ro-5083945
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04985825 | Phase 2 | Dec 31, 2021 | ICON, Pega-One S.A.S. |
| NCT01702714 | Phase 1 | Jul 1, 2014 | Roche |
| NCT01326000 | Phase 2 | Apr 1, 2011 | Roche |
| NCT01185847 | Phase 2 | Nov 1, 2010 | Roche |
| NCT01046266 | Phase 1 | Nov 1, 2009 | Roche |
| NCT00721266 | Phase 1 | Jun 1, 2008 | Roche |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Roche | For profit | 5 | 5 | 2 | 2008 |
| ICON | For profit | 1 | 0 | 1 | 2021 |
| Pega-One S.A.S. | For profit | 1 | 1 | 1 | 2021 |
3 organizations
Page 1 / 1